Tongjitang Pharmaceutical

Tongjitang Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and manufacturing of Traditional Chinese Medicine (TCM). The company is best known for its flagship product, Xianling Gubao, which is a leading treatment in China for osteoporosis and bone fractures. Founded with a heritage dating back to the late 19th century and modernized in the 1990s, it became the first TCM company to list on the New York Stock Exchange in 2007. Its product portfolio primarily focuses on orthopedics, rheumatology, and gynecology, utilizing proprietary herbal formulations. Although the parent entity faced significant regulatory challenges and delisting from the Shanghai Stock Exchange in 2022, the core manufacturing operations in Guizhou remain a major player in the Chinese TCM market.